

# **Establishing malaria parasite transfection technology in South Africa**

Anna C. van Brummelen, John V.W. Becker, Dalu Mancama  
and Heinrich C. Hoppe

CSIR Biosciences, P.O. Box 395, Pretoria, 0001, South Africa

*E-mail: tvbrummelen@csir.co.za*

## Introduction

- The most important contributing factor to the current malaria crisis is the **rapid spread of parasite resistance** to available anti-malarial drugs. Anti-malarial drug resistance is critical and the need for compounds with novel modes of action is beyond the point of urgency. A rational and a deliberate target-based drug discovery strategy as opposed to a “shotgun” screening-approach requires specific, well-characterized and **validated drug targets**.
- **Gene manipulation** is the only means by which the functions of individual proteins in living cells can confidently be confirmed and is thus **a fundamental requirement in target-based drug discovery**.

- Genetic manipulation of the malaria parasite, *Plasmodium falciparum*, is usually performed via **plasmid-based transfection** similar to those used in other eukaryotic organisms.
- However, a **major obstacle** faced by malaria research laboratories world-wide is the **poor transfection efficiencies** of current protocols due to the unique technical problems faced i.e. AT-richness and **intracellular location of the organism**.
- As a result successful transfection often requires **prolonged periods** (up to 2-3 months) of constant and patient culturing and selection. In addition, plasmids usually have a complicated composition and require lengthy cloning manipulations to prepare. **Improvements to the methodology would have wide impact and is constantly being sought.**

## Objectives

- To successfully transfect malaria parasites with foreign genes
- To improve malaria parasite transfection efficiency in order to shorten the transfectant selection time
- To use the technology to validate promising drug targets

## Methodology


- Parasite culture and transfection
  - *P. falciparum* 3D7 asexual cultures were maintained *in vitro* according to Trager and Jensen [1]
  - Parasites were transfected with 100 µg plasmid via electroporation (0.31 kV, 960 µF) [2]
  - Transfected parasites were selected for by 2.5 nM of the antifolate WR99210

- WR99210 culture media was changed daily for the first 6 days after which media was changed on alternative days until parasites appeared
- Parallel cultures were kept stationary and shaken at 50 rpm
- Cultures were visualized with microscopy
- Plasmid constructs
  - All constructs were prepared in NEB5 $\alpha$  *Escherichia coli* cells using standard molecular biology techniques
  - The pHTK plasmid [3] was used for insertion of a foreign gene (GFP, luciferase) to replace thymidine kinase in the transgene cassette – **control construct**
  - The promoters of both cassettes of pHTK [3] were replaced with a single bidirectional promoter, the *var* intron PFC0005w [4]. A foreign gene (GFP, luciferase) replaced thymidine kinase in the transgene site – **bidirectional construct**


- Foreign gene expression
  - GFP expression was visualized by fluorescence microscopy
  - Luciferase expression was determined by RT-PCR
    - DNase-treated RNA was reverse transcribed and amplified with luciferase-specific primers
    - PCR products were visualized by agarose gel electrophoresis

# Construct diagrams

## Control construct




## Bidirectional construct



Pb 3'- *Plasmodium berghei* 3' termination region; GFP- *Renilla reniformis* humanized recombinant green fluorescent protein II; PFC0005w- *var* intron [4]; hDHFR- human dihydrofolate reductase; hrp2 3'- histidine-rich protein 2 termination region; h86 5'- heat shock protein 86 promoter; CAM 5'- calmodulin promoter


## Results

- GFP-control construct



**Fig 1:** Bright field and fluorescence microscopy of GFP-control transfectants, only visible after 44 days, showing GFP expression.


- GFP-bidirectional construct



**Fig 2:** Bright field and fluorescence microscopy of GFP-bidirectional transfectants, already visible after 25 days, showing GFP expression



- Luciferase-bidirectional construct



**Fig 3:** Gel electrophoresis of luciferase transcripts of wild type parasites vs. luciferase-bidirectional transfectants, produced via RT-PCR with luciferase-specific primers. The foreign luciferase transcripts are not present in the wild type parasite but are visible in the transfectant rings and trophozoites after 20 amplification cycles.

- Stationary vs. shaken transfectants

**Table 1:** Number of days before transfected parasites appeared in stationary vs. shaken cultures

	Stationary	Shaken
GFP-bidirectional transfectants	32 days n = 1	26.5 ( $\pm 1.5$ ) days n = 2
Luciferase-bidirectional transfectants	34 ( $\pm 1$ ) days n = 2	28 days n = 1

– A similar result was recently reported [5]

## Conclusion

- Both the **control construct** and **bidirectional construct** successfully transfected *P. falciparum* parasites
- However, transfectants from the larger **control construct** took almost 20 days longer to appear
- The smaller **bidirectional construct** therefore significantly improved transfection efficiency
- Shaking the transfected cultures also resulted in a slightly reduced selection time compared to stationary cultures
- Malaria parasite transfection technology is now established in South Africa

## Future perspectives

- Applications:
  - The **control construct** (with separate promoters for the two cassettes) will be used to investigate transcriptional regulation (Promoter study)
  - The **bidirectional construct** will be used to determine the effect of overexpressing potential drug targets (Biomarker study)
  - Promising drug targets from functional genomics data are currently being validated
  - Two successful transfectants are under evaluation

## References

- [1] Trager W. and Jensen J. (1976) *Science*. **193**, 673-675.
- [2] Fidock D. and Wellems T. (1997) *PNAS*. **94**, 10931-10936.
- [3] Duraisingh M., Triglia T. and Cowman A. (2002) *Int. J. Parasitol.* **32**, 81-89.
- [4] Epp C., Raskolnikov D. and Deitsch, K. (2008) *Malaria Journal*. **7**, 86.
- [5] Allen R. and Kirk K. (2010) *Mol. Biochem. Parasitol.* **169**, 63-65.

## Acknowledgement

Claire Rossouw for assistance with cultures and photography